Editorial Commentary: Short-course oral corticosteroid therapy is not effective in early dengue infection

Clinical Infectious Diseases

Volumn 55, Issue 9, 2012, Pages 1225-1226

  Barrett, Alan D T ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CORTICOSTEROID; HEPARAN SULFATE; PLACEBO; PREDNISOLONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CORTICOSTEROID THERAPY; DENGUE; DENGUE VIRUS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNE RESPONSE; LIVER FUNCTION; LOW DRUG DOSE; NONHUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; TREATMENT OUTCOME; VIET NAM; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; DENGUE; FEMALE; HUMANS; MALE;

EID: 84867550875     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis657     Document Type: Note

References (12)

1. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8(12 suppl):S7-16.
2. Whitehorn J, Farrar J. Dengue. Br Med Bull 2010; 95:161-73.
3. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 11:532-43.
4. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011; 29: 587-619.
5. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29:7229-41.
6. Pastorino B, Nougairède A, Wurtz N, Gould Ede Lamballerie X. Role of host cell factors in flavivirus infection: implications for pathogenesis and development of antiviral drugs. Antiviral Res 2010; 87:281-94.
7. Blacksell SD, Jarman RG, Gibbons RV, et al. Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clin Vaccine Immunol 2012; 19: 804-10.
8. Bessoff K, Phoutrides E, Delorey M, Acosta LNHunsperger E. Utility of a commercial nonstructural protein 1 antigen capture kit as a dengue virus diagnostic tool. Clin Vaccine Immunol 2010; 17:949-53.
9. Loke P, Hammond SN, Leung JM, et al. Gene expression patterns of dengue virus-infected children from Nicaragua reveal a distinct signature of increased metabolism. PLoS Negl Trop Dis 2010; 4:e710-11.
10. Perera R, Kuhn RJ. Structural proteomics of dengue virus. Curr Opin Microbiol 2008; 11:369-77.
11. Noble CG, Chen YL, Dong H, et al. Strategies for development of dengue virus inhibitors. Antiviral Res 2010; 85:450-62.
12. Bollati M, Alvarez K, Assenberg R, et al. Structure and functionality in flavivirus NSproteins: perspectives for drug design. Antiviral Res 2010; 87:125-48.